JPMorgan Chase enters the week of October 13 earnings with a new wrinkle: the PCR spike that flagged defensiveness a week ago has faded, but the stock itself has caught up with the bearish signal — falling 3.5% on the week to $340, the sharpest decline in the peer group's upper tier.
The options story has actually resolved in a more constructive direction than last week's note implied. The put/call ratio pulled back to 1.10 from the 1.26 spike flagged seven days ago, now running about 0.9 standard deviations below its 20-day average of 1.15. That's a meaningful reversal. The prior week's defensive positioning has unwound rather than deepened — options traders appear to have taken profits on hedges after the stock moved lower. The 52-week range on PCR runs from 0.96 to 1.47, so the current reading sits near the middle, neither crowded with puts nor complacent. Short interest is similarly unexciting at under 1% of the free float — down nearly 2% on the week — and borrow conditions remain the loosest in the lending market, with availability running at its maximum recorded level and cost to borrow at just 0.21%, more than 40% cheaper than a month ago. There is no borrow pressure, no short squeeze tension, and no crowding in this name.
The selloff is better explained by the peer backdrop than by any JPM-specific deterioration. fell 5.6% on the week, dropped 7.3%, lost 6.8%, and even the more defensive shed 4.5%. JPM's 3.5% decline is the best performance among the large-cap names, consistent with its reputation as the sector's defensive anchor during risk-off episodes. The ORTEX short score remains anchored around 31, essentially flat for two weeks — no shift in the broader short-seller community's view of the name.
The Street retains a broadly constructive stance, though the most recent analyst actions are now over five weeks old. After last quarter's strong print in July, Wells Fargo raised its target to $390, UBS lifted to $400, and BofA bumped to $420 — all maintaining positive ratings. Citigroup and Baird sit at Neutral with targets of $360 and $305 respectively, the latter looking increasingly stale relative to current price levels. The consensus mean target of $375 implies roughly 10% upside from $340, a gap that has widened as the stock retraced its post-Q2 gains. Valuation is modest: P/E has compressed to 13.7x and P/B to 2.3x, both drifting lower over the past 30 days in line with the price move. The dividend yield factor ranks in the 95th percentile — among the highest in the universe — and the EPS surprise score at the 92nd percentile confirms the bank's track record of beating expectations. The bear case centres on NII pressure and the potential for credit volatility under CECL, neither of which has been the market's focus this week; the sector move looks macro-driven rather than credit-specific.
On the insider front, the recent trades carry no signal worth leaning on. The two open-market transactions in the past 90 days were both planned sales under 10b5-1 programmes — the Head of Human Resources sold small tranches in August and September at prices above current levels. Net insider activity over 90 days is a modest $3.6 million on the sell side, entirely consistent with scheduled programme execution rather than conviction-driven distribution.
With Q3 earnings set for October 13, the prior two quarters offer a useful reference. July's print drove a 3.7% one-day gain and held most of that over the following five sessions; the May quarter moved just 0.4% on day one. The setup heading in — a stock that has retraced its post-Q2 gains, a peer group under pressure, and options positioning no longer defensively crowded — makes the October print less about whether JPMorgan is growing and more about whether management's NII guidance can hold in a macro environment that has clearly rattled the bank sector this week.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
